A-R Hartman

518 total citations
10 papers, 130 citations indexed

About

A-R Hartman is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, A-R Hartman has authored 10 papers receiving a total of 130 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 5 papers in Cancer Research and 4 papers in Oncology. Recurrent topics in A-R Hartman's work include DNA Repair Mechanisms (5 papers), Cancer Genomics and Diagnostics (4 papers) and PARP inhibition in cancer therapy (3 papers). A-R Hartman is often cited by papers focused on DNA Repair Mechanisms (5 papers), Cancer Genomics and Diagnostics (4 papers) and PARP inhibition in cancer therapy (3 papers). A-R Hartman collaborates with scholars based in United States, Canada and Germany. A-R Hartman's co-authors include Kirsten M. Timms, Andrew K. Godwin, Yulia Y. Tyurina, C. Thompson, Valerian E. Kagan, Charles M. Rudin, Priyanka Sharma, Gabriel N. Hortobágyi, Daniel F. Hayes and Nina F. Schor and has published in prestigious journals such as Cancer Research, Oncogene and Annals of Oncology.

In The Last Decade

A-R Hartman

10 papers receiving 129 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A-R Hartman United States	5	90	82	44	28	25	10	130
Stacey E. P. Joosten Netherlands	7	65 0.7×	91 1.1×	54 1.2×	32 1.1×	58 2.3×	9	184
Fedor V. Moiseyenko Russia	8	77 0.9×	52 0.6×	44 1.0×	58 2.1×	18 0.7×	17	126
Verena Thewes Germany	7	57 0.6×	71 0.9×	60 1.4×	30 1.1×	48 1.9×	14	148
Mike R. Zou United States	5	69 0.8×	327 4.0×	61 1.4×	40 1.4×	28 1.1×	5	373
Rhiannon Coulson Australia	5	91 1.0×	73 0.9×	32 0.7×	72 2.6×	27 1.1×	6	157
Shucai Zhang China	9	61 0.7×	110 1.3×	49 1.1×	36 1.3×	12 0.5×	16	159
Colleen Niland Australia	7	41 0.5×	69 0.8×	35 0.8×	30 1.1×	5 0.2×	8	110
Andrew Barthorpe United Kingdom	3	67 0.7×	147 1.8×	57 1.3×	16 0.6×	18 0.7×	3	213
Martyna Marani United Kingdom	4	78 0.9×	172 2.1×	34 0.8×	18 0.6×	33 1.3×	4	216
Tajinder Ubhi Canada	4	71 0.8×	140 1.7×	28 0.6×	15 0.5×	7 0.3×	4	161

Countries citing papers authored by A-R Hartman

Since Specialization

Citations

This map shows the geographic impact of A-R Hartman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A-R Hartman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A-R Hartman more than expected).

Fields of papers citing papers by A-R Hartman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A-R Hartman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A-R Hartman. The network helps show where A-R Hartman may publish in the future.

Co-authorship network of co-authors of A-R Hartman

This figure shows the co-authorship network connecting the top 25 collaborators of A-R Hartman. A scholar is included among the top collaborators of A-R Hartman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A-R Hartman. A-R Hartman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Rini, Brian I., Jun Zhang, O. Hall, et al.. (2023). 1910P Evaluation of a genome-wide methylome enrichment platform for circulating tumor DNA quantification and prognostic performance in renal cell carcinoma (RCC). Annals of Oncology. 34. S1028–S1028. 1 indexed citations

Liu, Geoffrey, Jun Zhang, O. Hall, et al.. (2023). 866P Prognostic performance of a genome-wide methylome enrichment platform in head and neck cancer. Annals of Oncology. 34. S561–S561. 1 indexed citations

Liu, MC, Steven R. Cummings, CM Vachon, et al.. (2018). Abstract OT3-02-01: Development of cell-free nucleic acid-based tests for early detection of breast cancer: The STRIVE study. Cancer Research. 78(4_Supplement). OT3–2. 3 indexed citations

Sharma, Priyanka, William E. Barlow, Andrew K. Godwin, et al.. (2017). Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313). Annals of Oncology. 29(3). 654–660. 64 indexed citations

McMillan, A, SJ Isakoff, VG Kaklamani, et al.. (2016). Abstract P3-07-12: Homologous recombination deficiency (HRD) as a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple negative breast cancer (TNBC): A pooled analysis. Cancer Research. 76(4_Supplement). P3–7. 11 indexed citations

Connolly, Roisín M., Eric P. Elkin, Kirsten M. Timms, et al.. (2016). Abstract P3-07-13: Homologous recombination deficiency (HRD) as a predictive biomarker of response to preoperative systemic therapy (PST) in TBCRC008 comprising a platinum in HER2-negative primary operable breast cancer. Cancer Research. 76(4_Supplement). P3–7. 3 indexed citations

Ring, Kari L., Amanda Bruegl, Brian Allen, et al.. (2016). Hereditary cancer panel testing in an unselected endometrial carcinoma cohort. Gynecologic Oncology. 141. 10–11. 4 indexed citations

Isakoff, SJ, Tiffany A. Traina, LA Carey, et al.. (2012). Abstract PD09-03: Impact of BRCA1/2 Mutation Status in TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple negative breast cancer.. Cancer Research. 72(24_Supplement). PD09–3. 5 indexed citations

Abkevich, Victor, et al.. (2012). Abstract PD09-04: Homologous Recombination Deficiency (HRD) score predicts pathologic response following neoadjuvant platinum-based therapy in triple-negative and BRCA1/2 mutation-associated breast cancer (BC). Cancer Research. 72(24_Supplement). PD09–4. 6 indexed citations

10.

Schor, Nina F., Charles M. Rudin, A-R Hartman, et al.. (2000). Cell line dependence of Bcl-2-induced alteration of glutathione handling. Oncogene. 19(3). 472–476. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact